News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
524,908 Results
Type
Article (44687)
Company Profile (121)
Press Release (480100)
Section
Business (144927)
Career Advice (2398)
Deals (27933)
Drug Delivery (118)
Drug Development (67953)
Employer Resources (148)
FDA (15616)
Job Trends (11950)
News (263621)
Policy (29604)
Tag
Academia (2288)
Alliances (35931)
Alzheimer's disease (1376)
Approvals (15564)
Artificial intelligence (201)
Bankruptcy (306)
Best Places to Work (9197)
Breast cancer (219)
Cancer (1678)
Cardiovascular disease (139)
Career advice (1999)
CAR-T (125)
Cell therapy (359)
Clinical research (54791)
Collaboration (593)
Compensation (382)
COVID-19 (2582)
C-suite (166)
Data (1571)
Diabetes (220)
Diagnostics (5209)
Earnings (57965)
Employer resources (135)
Events (76183)
Executive appointments (527)
FDA (16554)
Funding (526)
Gene therapy (268)
GLP-1 (729)
Government (3841)
Healthcare (14799)
Infectious disease (2702)
Inflammatory bowel disease (118)
Interviews (448)
IPO (13959)
Job creations (3155)
Job search strategy (1665)
Layoffs (483)
Legal (6945)
Lung cancer (241)
Manufacturing (233)
Medical device (11145)
Medtech (11148)
Mergers & acquisitions (14340)
Metabolic disorders (610)
Neuroscience (1801)
NextGen: Class of 2025 (4984)
Non-profit (3164)
Northern California (2027)
Obesity (346)
Opinion (208)
Patents (173)
People (42366)
Phase I (16385)
Phase II (23725)
Phase III (19490)
Pipeline (796)
Policy (117)
Postmarket research (2205)
Preclinical (6580)
Radiopharmaceuticals (206)
Rare diseases (340)
Real estate (4254)
Regulatory (20675)
Research institute (2054)
Resumes & cover letters (401)
Southern California (1685)
Startups (2741)
United States (17071)
Vaccines (695)
Weight loss (266)
Date
Today (159)
Last 7 days (773)
Last 30 days (2676)
Last 365 days (30878)
2025 (5079)
2024 (31406)
2023 (34982)
2022 (45057)
2021 (48498)
2020 (45510)
2019 (36210)
2018 (27397)
2017 (27804)
2016 (25804)
2015 (27973)
2014 (21774)
2013 (17791)
2012 (18963)
2011 (19382)
2010 (17504)
Location
Africa (670)
Arizona (152)
Asia (30867)
Australia (5417)
California (4503)
Canada (1305)
China (326)
Colorado (201)
Connecticut (232)
Europe (75000)
Florida (677)
Georgia (148)
Illinois (376)
Indiana (212)
Maryland (717)
Massachusetts (3429)
Michigan (161)
Minnesota (284)
New Jersey (1293)
New York (1254)
North Carolina (785)
Northern California (2027)
Ohio (140)
Pennsylvania (991)
South America (1033)
Southern California (1685)
Texas (632)
Utah (124)
Washington State (432)
524,908 Results for "symphogen a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
IPO
‘Valentine’s Day Massacre’: Deerfield Claims Alcon is Blocking Aurion’s IPO
Deerfield Management claims that Alcon Research is seeking a discounted takeover of Aurion Biotech while blocking the startup’s efforts to go public.
February 25, 2025
·
2 min read
·
Tristan Manalac
Podcast
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III; Amgen’s MariTide fails to impress investors, Donald Trump’s controversial nominations continue.
November 27, 2024
·
1 min read
·
Heather McKenzie
Regulatory
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a third-party provider while releasing Amylyx’s investigational ALS therapy from a previous pause.
January 22, 2025
·
2 min read
·
Tristan Manalac
Deals
Servier Completes the Acquisition of Symphogen
Servier, an independent international pharmaceutical company, today announced that it has completed the acquisition of Symphogen A/S. Symphogen will now function as Servier’s antibody center of excelle
June 4, 2020
·
2 min read
Neurodegenerative disease
Inhibikase Scraps Parkinson’s Drug After Disappointing Mid-Stage Data
Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and abandoned assets in recent months.
January 30, 2025
·
2 min read
·
Tristan Manalac
Cancer
The Search for the Next Keytruda: Immuno-Oncology’s Next Play
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a crossroads, with experts highlighting novel targets, combinations and pre-emptive immunization as the next wave for IO.
March 3, 2025
·
7 min read
·
Heather McKenzie
NextGen
BioSpace
’s NextGen Class of 2025 Leans Into Biopharma’s Hottest Trends
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.
January 7, 2025
·
5 min read
·
Heather McKenzie
Drug Delivery
Explainer: The Thriving Shadow Market of GLP-1s for Weight Loss
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing potential risks to the public.
February 11, 2025
·
5 min read
·
Ben Hargreaves
Alzheimer’s disease
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
January 23, 2025
·
2 min read
·
Dan Samorodnitsky
Rare diseases
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to compete in the hemophilia A space with Roche’s
blockbuster
Hemlibra.
February 7, 2025
·
2 min read
·
Dan Samorodnitsky
1 of 52,491
Next
